Research graph
References from Formulation and Delivery Strategies for Current and Next-Generation Live-Attenuated Measles and Rubella Containing Vaccines. Local targets link to admitted publications; unresolved targets remain external evidence.
Measles.
10.1016/s0140-6736(21)02004-3 · 2022 · External reference
On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia.
10.3390/vaccines12090957 · 2024 · External reference
The basic reproduction number (R0) of measles: a systematic review.
10.1016/s1473-3099(17)30307-9 · 2017 · External reference
Measles Vaccine.
10.1089/vim.2017.0143 · 2017 · External reference
Rubella.
10.1016/s0140-6736(21)02691-x · 2022 · External reference
Molecular and Structural Insights into the Life Cycle of Rubella Virus.
10.1128/jvi.02349–02320 · 2021 · External reference
Measles immunity and immunosuppression.
10.1016/j.coviro.2020.08.002 · 2021 · External reference
CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells.
10.1007/s002510100337 · 2001 · External reference
Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens.
10.1126/science.aay6485 · 2019 · External reference
Efficiency of Measles Virus Entry and Dissemination through Different Receptors.
10.1128/jvi.76.15.7460-7467.2002 · 2002 · External reference
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
10.1080/21645515.2015.1122146 · 2016 · External reference
Rubella.
External reference
Rubella (German Measles) and Congenital Deformities.
10.1056/nejm194902172400706 · 1949 · External reference
Estimates of the basic reproduction number for rubella using seroprevalence data and indicator-based approaches.
10.1371/journal.pcbi.1008858 · 2022 · External reference
Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus.
10.1001/archpedi.1965.02090030401007 · 1965 · External reference
The History of Rubella and Rubella Vaccination Leading to Elimination.
10.1086/505950 · 2006 · External reference
Identification of the Myelin Oligodendrocyte Glycoprotein as a Cellular Receptor for Rubella Virus.
10.1128/jvi.05398-11 · 2011 · External reference
Measles.
10.1016/s0140-6736(10)62352-5 · 2012 · External reference
SIB Swiss Institute of Bioinformatics. Matonaviridae.
External reference
Progress Toward Measles Elimination — Worldwide, 2000–2023.
10.15585/mmwr.mm7345a4 · 2024 · External reference
Measles once again.
10.1016/s1473-3099(11)70152-9 · 2011 · External reference
Progress Toward Rubella and Congenital Rubella Syndrome Elimination — Worldwide, 2012–2022.
10.15585/mmwr.mm7308a2 · 2024 · External reference
Measles and Measles-Rubella Combination Vaccines: Supply and Demand Update.
External reference
Measles 2025.
10.1056/nejmra250451610.1056/nejmra2504516 · 2025 · External reference
Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US.
10.1001/jama.2025.6495 · 2025 · External reference
WHO-CDC measles report & the State of measles vaccination in lower-income countries.
2024 · External reference
Measles Cases Rise Globally, While the Americas Region Regains Measles Elimination Status.
External reference
PAHO Calls for Regional Action as the Americas Lose Measles Elimination Status.
External reference
14th Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC).
External reference
Progress towards measles elimination - worldwide, 2000–2024.
10.15585/mmwr.mm7345a4 · 2025 · External reference
Progress Toward Rubella and Congenital Rubella Syndrome Elimination - Worldwide, 2012-2024.
10.15585/mmwr.mm7528a1 · 2026 · External reference
The path to eradication of rubella.
10.1016/j.vaccine.2023.11.014 · 2023 · External reference
Progress Toward Rubella Elimination — World Health Organization European Region, 2005–2019.
10.15585/mmwr.mm7023a1 · 2021 · External reference
Twelfth meeting of the European Regional Verification Commission for Measles and Rubella Elimination.
External reference
Genetic characterization of measles vaccine strains.
10.1093/infdis/jir097 · 2011 · External reference
Rubella vaccines: past, present and future.
10.1017/s0950268800048640 · 1991 · External reference
Enders and measles virus vaccine--a reminiscence.
10.1007/978-3-540-70523-9_1 · 2009 · External reference
Measles 50 Years After Use of Measle Vaccine.
10.1016/j.idc.2015.08.001 · 2015 · External reference
MMR and MMRV vaccines.
10.1016/j.vaccine.2017.07.051 · 2018 · External reference
Making Vaccination Policy: The Experience with Rubella.
10.1086/515062 · 1999 · External reference
Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5–6 years.
10.1016/j.jiac.2024.06.011 · 2024 · External reference
Measles Vaccination Before the Measles-Mumps-Rubella Vaccine.
10.2105/ajph.2012.301075 · 2013 · External reference
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.
10.1038/nm918 · 2003 · External reference
Measles Prevention.
External reference
Edmonston-Zagreb Strain of Measles Vaccine: Epidemiologic Evaluation in Yugoslavia.
10.1093/clinids/5.3.558 · 1983 · External reference
Measles vaccines: WHO position paper - April 2017.
External reference
Child Mortality Following Standard, Medium or High Titre Measles Immunization in West Africa.
10.1093/ije/25.3.665 · 1996 · External reference
Progress towards rubella elimination after implementation of rubella immunization for over 20 years in Shandong province, China.
10.1038/s41598-017-18281-2 · 2017 · External reference
Vaccine History Timeline.
External reference
Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
10.1037/e547602006-001 · 1998 · External reference
History of measles vaccination.
External reference
Measles, Mumps, Rubella Vaccine (Priorix; GSK-MMR) A Review of its Use in the Prevention of Measles, Mumps and Rubella.
10.2165/00003495-200363190-00012 · 2003 · External reference
M-M-R® II (measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.): Product Monograph.
External reference
M-M-R II (measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.).
External reference
Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.
10.1001/jama.225.6.585 · 1973 · External reference
Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022.
10.15585/mmwr.mm7146a1 · 2022 · External reference
Recommended Childhood Immunization Schedule: United States — 1995.
10.1177/000992289503400201 · 1995 · External reference
Requirements for measles, mumps and rubella vaccines and combined vaccines (live).
External reference
FAQs Regarding the MR (Measles Rubella) Vaccine.
External reference
Global Market Study: Measles-Containing Vaccines (MCV).
External reference
Prequalified Vaccines.
External reference
Vaccines Licensed for Use in the United States.
External reference
M-M-R® II product monograph.
External reference
ProQuad®product monograph.
External reference
Vaccine Vial Monitor: PQS Performance Specification WHO/PQS/E006/IN05.3.
External reference
WHO policy statement: Multi-dose vial policy (MDVP).
External reference
CTD Preparation and Submission.
External reference
WHO Policy Statement: Multi-dose Vial Policy (MDVP).
External reference
Measles vaccine, live attenuated (freeze-dried): package insert.
External reference
Measles vaccine: package insert.
External reference
Rubella vaccine, live attenuated (freeze-dried): package insert.
External reference
Summary of Product Characteristics: Measles and Rubella Vaccine (Live) I.P. [MR-VAC].
External reference
Measles and rubella vaccine, live attenuated (freeze-dried): package insert.
External reference
Limited. MRBEV® Measles and Rubella Vaccine (Live) (Attenuated, Freeze-dried) – Summary of Product Characteristics.
External reference
Limited. International marketing catalogue: vaccines (including MRBEV measles and rubella vaccine).
External reference
Summary of Product Characteristics — MMR Vaccine.
External reference
Summary of Product Characteristics: Measles, Mumps and Rubella Vaccine (Live) I.P. [TRESIVAC].
External reference
M-M-R® II product monograph.
External reference
Package Insert - Priorix.
External reference
ProQuad®product monograph.
External reference
Priorix-Tetra (measles, mumps, rubella and varicella vaccine, live, attenated): product monograph.
External reference
ミールビックII皮下注用 [MEARUBIK II Subcutaneous Injection Package Insert].
External reference
はしか風しん混合生ワクチン「北里第一三共」医薬品インタビューフォーム [Measles-Rubella Combined Live Vaccine "Kitasato Daiichi Sankyo" Drug Interview Form].
External reference
Freeze-Dried Live Attenuated Measles and Rubella Combined Vaccine “Takeda” (乾燥弱毒生麻しん風しん混合ワクチン「タケダ」): Package Insert.
External reference
Heisei 17 Fiscal Year Approved Products List (New Drugs) (平成17年度承認品目一覧(新医薬品)).
External reference
麻疹风疹联合减毒活疫苗:产品标签 - Measles and rubella combined vaccine, live: product label.
External reference
麻疹风疹联合减毒活疫苗:说明书 - Measles and rubella combined vaccine, live: product instruction.
External reference
麻腮风联合减毒活疫苗:产品标签 - Measles, mumps and rubella combined vaccine, live: product label.
External reference
麻腮风联合减毒活疫苗:说明书 - Measles, mumps and rubella combined vaccine, live: product instruction.
External reference
ВАКТРИВИР Комбинированная вакцина против кори, краснухи и паротита культуральная живая: Инструкция по медицинскому применению лекарственного препарата - VAKTRIVIR Combined vaccine against measles, rubella and mumps, live cultural: Instructions for medical use of the medicinal product.
External reference
Principles of vaccine potency assays.
10.4155/bio-2017-0176 · 2018 · External reference
Improved potency assay of rubella vaccine: parameters for plaque formation.
10.1016/0166-0934(94)00127-3 · 1995 · External reference
Manual of laboratory methods for testing of vaccines used in the WHO Expanded Programme on Immunization.
External reference
Formulation Development and Improved Stability of a Combination Measles and Rubella Live-Viral Vaccine Dried for Use in the Nanopatch (TM) Microneedle Delivery System.
10.1080/21645515.2021.1887692 · 2021 · External reference
Time to revisit the endpoint dilution assay and to replace the TCID50 as a measure of a virus sample's infection concentration.
10.1371/journal.pcbi.1009480 · 2021 · External reference
VaxArray® Measles and Rubella Assay Correlationto CCID50.
External reference
Rapid Viral Infectivity Measurements that Replace Plaque and TCID50 Assays.
External reference
A versatile automated pipeline for quantifying virus infectivity by label-free light microscopy and artificial intelligence.
10.1038/s41467-024-49444-1 · 2024 · External reference
Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq).
10.1016/j.jviromet.2005.08.013 · 2006 · External reference
Measles Vaccine (Live).
2005 · External reference
National Control Laboratories.
External reference
Guidelines on the replacement or removal of animal tests for the quality control of biological products.
External reference
WHO expert committee on biological standardization.
External reference
Monitoring progress toward measles elimination by genetic diversity analysis of measles viruses in China 2009-2010.
10.1111/1469-0691.12530 · 2014 · External reference
Measles: old vaccines, new vaccines.
10.1007/978-3-540-70617-5_10 · 2009 · External reference
Application note. Scale-X™ fixed-bed bioreactor for vaccine manufacturing.
External reference
Rapid response, low-cost manufacturing of viral vaccines against emerging infectious disease threats.
External reference
Case Study on Formulating a Multidose Lyophilized Measles-Rubella (MR) Vaccine Candidate for Local Manufacturing in Africa: Lab-Scale Results and Lessons-Learned for Future Technology Transfer.
10.12688/verixiv.3696.1 · 2026 · External reference
Development of a New Lyophilized Live-Attenuated Measles-Rubella (MR) Vaccine Formulation Designed for Lower Cost Production in Africa.
10.12688/verixiv.3696.1 · 2026 · External reference
Measles Vaccine (Live) Summary of Product Characteristics.
External reference
Multicenter Safety and Immunogenicity Trial of an Attenuated Measles Vaccine for NHP.
2015 · External reference
Viral Vaccines in India: An Overview.
10.1007/s40011-011-0014-9 · 2012 · External reference
Development of a measles vaccine production process in MRC-5 cells grown on Cytodex1 microcarriers and in a stirred bioreactor.
10.1007/s00253-011-3574-y · 2012 · External reference
Suspended cell lines for inactivated virus vaccine production.
10.1080/14760584.2023.2214219 · 2023 · External reference
Formulation and production of a blood-free and chemically defined virus production media for VERO cells.
10.1002/bit.27486 · 2020 · External reference
Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
1986 · External reference
Towards ambient temperature-stable vaccines: The identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay.
10.1016/j.vaccine.2011.04.079 · 2011 · External reference
Formulation, stability, and delivery of live attenuated vaccines for human use.
10.1615/critrevtherdrugcarriersyst.v16.i1.10 · 1999 · External reference
083 Thermostabilization of measles vaccines using preservation by vaporization.
10.1016/j.cryobiol.2013.09.089 · 2013 · External reference
Measles Virus Structural Components Are Enriched into Lipid Raft Microdomains: a Potential Cellular Location for Virus Assembly.
10.1128/jvi.74.1.305-311.2000 · 2000 · External reference
Phospholipids in a Measles Virus Persistent Infection: Modification of Fatty Acid Metabolism and Fatty Acid Composition of Released Virus.
10.1099/0022-1317-62-2-249 · 1982 · External reference
Recent Development of Optimization of Lyophilization Process.
10.1155/2019/9502856 · 2019 · External reference
Design of freeze-drying processes for pharmaceuticals: practical advice.
10.1023/b:pham.0000016234.73023.75 · 2004 · External reference
Lyophilization of Adjuvanted Vaccines: Methods for Formulation of a Thermostable Freeze-Dried Product.
10.1007/978-1-4939-6445-1_15 · 2017 · External reference
Freeze-drying of live virus vaccines: A review.
10.1016/j.vaccine.2015.08.085 · 2015 · External reference
Stability of lyophilized and spray dried vaccine formulations.
10.1016/j.addr.2021.01.016 · 2021 · External reference
Drying of Vaccines and Biomolecules.
10.1080/07373937.2020.1825293 · 2020 · External reference
Vaccine Stabilizer.
External reference
Sorbitol-gelatin and glutamic acid-lactose solutions for stabilization of reference preparations of measles virus.
1989 · External reference
Stabilizing Vaccines.
External reference
Formulation and stability design spaces for a new yellow fever vaccine.
10.1016/j.ejpb.2026.115177 · 2026 · External reference
A small molecule chemical chaperone optimizes its unfolded state contraction and denaturant like properties.
10.1038/srep03525 · 2013 · External reference
Requirements for Measles, Mumps and Rubella Vaccines and Combined Vaccine (Live) (Requirements for Biological Substances No. 47).
External reference
Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction, and/or immobilization in a glassy matrix?.
10.1002/jps.20364 · 2005 · External reference
Stabilization of measles virus for vaccine formulations.
10.4161/hv.4.5.5863 · 2008 · External reference
Characterization of Phosphate Buffered Saline (PBS) in Frozen State and after Freeze-Drying.
10.1007/s11095-019-2619-2 · 2019 · External reference
Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state.
10.1002/jps.20363 · 2005 · External reference
Preserving dry biomaterials: The water replacement hypothesis.
1993 · External reference
Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice.
10.1023/a:1012180707283 · 1997 · External reference
Oral lyophilizates obtained using aggressive drying conditions: Effect of excipients.
10.1016/j.jddst.2023.104379 · 2023 · External reference
Optimizing Your Excipient Screening for Vaccine Formulation with an Ultra-Pure Pharmaceutical Gelatin. Optimizing Your Excipient Screening for Vaccine Formulation with an Ultra-Pure Pharmaceutical Gelatin.
External reference
Mannitol as an Excipient for Lyophilized Injectable Formulations.
10.1016/j.xphs.2022.08.029 · 2023 · External reference
Mannitol-sucrose mixtures--versatile formulations for protein lyophilization.
10.1002/jps.10094 · 2002 · External reference
Factors affecting the stability of viral vaccines.
1996 · External reference
Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers.
10.1016/j.jviromet.2018.08.013 · 2019 · External reference
Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.
10.1097/01.inf.0000091887.48999.77 · 2003 · External reference
Temperature sensitivity of vaccines.
External reference
Influence of Process Conditions on Measles Virus Stability.
10.3844/ajbbsp.2013.243.254 · 2013 · External reference
Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses.
10.3390/vaccines13050444 · 2025 · External reference
Stability, biophysical properties and effect of ultracentrifugation and diafiltration on measles virus and mumps virus.
10.1007/s00705-016-2801-3 · 2016 · External reference
Rubella virus contains one capsid protein and three envelope glycoproteins, E1, E2a, and E2b.
10.1128/jvi.46.3.964-973.1983 · 1983 · External reference
Analysis of Morphology and Infectivity of Measles Virus Particles.
2007 · External reference
Molecular determinants of the ratio of inert to infectious virus particles.
10.1016/bs.pmbts.2014.10.012 · 2015 · External reference
Growth and stability of measles virus.
10.1016/0042-6822(59)90186-2 · 1959 · External reference
Forced Degradation Studies to Identify Critical Process Parameters for the Purification of Infectious Measles Virus.
10.3390/v11080725 · 2019 · External reference
An accelerated stability test procedure for lyophilized measles vaccines.
10.1016/s0092-1157(81)80022-4 · 1981 · External reference
A study of the stability of a bivalent measles--mumps vaccine.
10.1016/s0092-1157(82)80011-5 · 1982 · External reference
A scalable, integrated downstream process for production of a recombinant measles virus-vectored vaccine.
10.1016/j.vaccine.2022.01.004 · 2022 · External reference
Photoinactivation of measles virus.
10.1016/0042-6822(62)90137-x · 1962 · External reference
The antioxidant properties of serum albumin.
10.1016/j.febslet.2008.04.057 · 2008 · External reference
Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization.
10.1002/bit.260480511 · 1995 · External reference
Stability of protein pharmaceuticals.
10.1023/a:1015929109894 · 1989 · External reference
Self-Interaction of Human Serum Albumin: A Formulation Perspective.
10.1021/acsomega.8b02245 · 2018 · External reference
Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects.
10.1016/j.bpc.2006.12.007 · 2007 · External reference
Preferential interaction coefficients of proteins in aqueous arginine solutions and their molecular origins.
10.1021/jp108586b · 2011 · External reference
Investigation of the thermal shift assay and its power to predict protein and virus stabilizing conditions.
10.1016/j.jpba.2018.08.017 · 2018 · External reference
Temperature-and UV-light resistance of rubella virus infectivity.
10.1007/bf01241351 · 1972 · External reference
Low pH-induced Conformational Change of Rubella Virus Envelope Proteins.
10.1099/0022-1317-69-11-2797 · 1988 · External reference
Rubella virus mutations that confer resistance to inactivation at low pH.
10.1128/jvi.00255-25 · 2025 · External reference
Photodynamic Inactivation Of Rubella Virus.
10.1099/00222615-5-4-515 · 1972 · External reference
Current progress in pulmonary delivery of measles vaccine.
10.1586/14760584.2014.915753 · 2014 · External reference
Alternative routes of measles immunization: a review.
10.1006/biol.1997.0103 · 1997 · External reference
Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine.
10.1128/cvi.00354-10 · 2011 · External reference
Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis.
10.1016/j.vaccine.2007.11.010 · 2008 · External reference
A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
10.1073/pnas.2220403120 · 2023 · External reference
Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.
10.1038/s41467-024-49443-2 · 2024 · External reference
A randomized, controlled trial of an aerosolized vaccine against measles.
10.1056/nejmoa1407417 · 2015 · External reference
Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial.
10.1016/j.vaccine.2014.09.071 · 2014 · External reference
Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial.
10.1016/s0140-6736(99)95140-1 · 2000 · External reference
It's time to change how we vaccinate for measles.
10.1016/j.vaccine.2025.127382 · 2025 · External reference
Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine.
10.1089/jamp.2007.0658 · 2008 · External reference
Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation.
10.1016/j.vaccine.2010.10.020 · 2011 · External reference
Heat-stable measles vaccine produced by spray drying.
10.1016/j.vaccine.2009.11.024 · 2010 · External reference
Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques.
10.1073/pnas.1017334108 · 2011 · External reference
Stabilizers for lyophilized vaccines.
External reference
Stabilizers for live vaccines. U.S. Patent No. 6,231,860.
External reference
Lyophilization process for live viral compositions.
External reference
Targeting skin dendritic cells to improve intradermal vaccination.
10.1007/82_2010_118 · 2012 · External reference
Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges.
10.3389/fpubh.2022.809675 · 2022 · External reference
Microarray patches: scratching the surface of vaccine delivery.
10.1080/14760584.2023.2270598 · 2023 · External reference
A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.
10.1016/j.coviro.2020.05.005 · 2020 · External reference
Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the Nanopatch™ microprojection array.
10.1016/j.xphs.2018.01.027 · 2018 · External reference
Development of a thermostable microneedle patch for influenza vaccination.
10.1002/jps.24283 · 2015 · External reference
Developing a stabilizing formulation of a live chimeric dengue virus vaccine dry coated on a high-density microarray patch.
10.3390/vaccines9111301 · 2021 · External reference
Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects.
10.1016/j.biomaterials.2017.02.040 · 2017 · External reference
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
10.1016/s0140-6736(24)00532-4 · 2024 · External reference
Microneedle-Based Vaccine Delivery: Review of an Emerging Technology.
10.1208/s12249-022-02250-8 · 2022 · External reference
Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.
10.1002/adtp.202100095 · 2021 · External reference
A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.
10.1093/infdis/jiy139 · 2018 · External reference
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.
10.3390/vaccines11111725 · 2023 · External reference
Measles vaccination using a microneedle patch.
10.1016/j.vaccine.2012.09.062 · 2013 · External reference
Usability of two microarray patch designs for the delivery of measles-rubella vaccine: A three-country study.
2026 · External reference
A microneedle patch containing measles vaccine is immunogenic in non-human primates.
10.1016/j.vaccine.2015.02.074 · 2015 · External reference
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naive infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
10.1186/s13063-022-06493-5 · 2022 · External reference
Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial.
10.1016/j.vaccine.2014.09.071 · 2014 · External reference
Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.
10.1007/s13346-022-01130-9 · 2022 · External reference
Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
10.1016/j.vaccine.2025.126996 · 2025 · External reference
Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective.
10.1080/21645515.2022.2050123 · 2022 · External reference
Effective Approaches to Combat Vaccine Hesitancy.
10.1097/inf.0000000000003499 · 2022 · External reference
Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.
10.1016/j.vaccine.2025.126950 · 2025 · External reference
Attenuated measles virus as a vaccine vector.
10.1016/j.vaccine.2007.01.064 · 2007 · External reference
Programming cytomegalovirus as an HIV vaccine.
10.1016/j.it.2023.02.001 · 2023 · External reference
Large-scale and cost-effective production of recombinant human serum albumin (rHSA) in transgenic Bombyx mori cocoons.
10.1016/j.ijbiomac.2023.125527 · 2023 · External reference
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.
10.1016/j.heliyon.2024.e34927 · 2024 · External reference
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.
10.1093/infdis/jiaa530 · 2021 · External reference
